Swedish Orphan Biovitrum (BIOVF)
(Delayed Data from OTC)
$25.76 USD
+2.89 (12.62%)
Updated May 3, 2024 09:52 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Swedish Orphan Biovitrum falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,086 | 1,862 | 1,811 | 1,663 | 1,507 |
Cost Of Goods | 471 | 473 | 406 | 352 | 353 |
Gross Profit | 1,615 | 1,389 | 1,404 | 1,312 | 1,155 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,232 | 1,011 | 969 | 787 | 675 |
Income After Depreciation & Amortization | 383 | 378 | 435 | 525 | 480 |
Non-Operating Income | NA | 1 | 2 | 0 | 1 |
Interest Expense | 105 | 49 | 53 | 66 | 31 |
Pretax Income | 279 | 329 | 384 | 460 | 449 |
Income Taxes | 51 | 68 | 72 | 106 | 100 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 227 | 261 | 312 | 354 | 350 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 227 | 261 | 312 | 354 | 350 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 685 | 617 | 669 | 746 | 648 |
Depreciation & Amortization (Cash Flow) | 302 | 240 | 234 | 221 | 168 |
Income After Depreciation & Amortization | 383 | 378 | 435 | 525 | 480 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 325.97 | 298.45 | 296.80 | 298.02 | 294.53 |
Diluted EPS Before Non-Recurring Items | 0.80 | 1.06 | 1.05 | 1.04 | 1.25 |
Diluted Net EPS (GAAP) | 0.70 | 0.88 | 1.05 | 1.19 | 1.19 |
Fiscal Year end for Swedish Orphan Biovitrum falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 601.91 | 643.39 | 478.04 | 462.84 | 500.85 |
Cost Of Goods | NA | 130.64 | 108.04 | 130.34 | 102.01 |
Gross Profit | NA | 513.83 | 370.00 | 332.50 | 398.84 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 363.26 | 319.41 | 293.17 | 256.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 150.57 | 50.59 | 39.33 | 142.83 |
Non-Operating Income | NA | NA | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 35.63 | 39.87 | 13.11 | 16.25 |
Pretax Income | NA | 115.04 | 10.73 | 26.13 | 126.67 |
Income Taxes | NA | 19.66 | 2.04 | 5.13 | 24.66 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 76.97 | 96.45 | 8.70 | 21.00 | 102.01 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 76.97 | 96.45 | 8.70 | 21.09 | 102.01 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 344.07 | 342.88 | 318.80 | 300.00 | 296.39 |
Diluted EPS Before Non-Recurring Items | 0.26 | 0.30 | 0.05 | 0.14 | 0.34 |
Diluted Net EPS (GAAP) | 0.22 | 0.28 | 0.03 | 0.07 | 0.34 |